Companies · Biotech / Pharma

Recreo Pharmaceuticals Llc

SUPERIOR · Biotech / Pharma · refined from filed group “Other

Diligence memoA one-page analyst read on Recreo Pharmaceuticals Llc — recommendation, valuation, rhythm, risks.
$3.2M
Total raised · real
2
Rounds
12.0×
Latest step-up
Top 58%
Sector rank · raised
Seed
Latest stage · inferred · Wed Nov 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Recreo Pharmaceuticals Llc has raised $3.2M over 2 rounds; too few niche peers to rank its valuation yet.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech/pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Dormant
  • Last raise 8.7 yr ago; this sector typically re-raises about every 15 months.
  • Silent for over 3× the sector's normal cadence.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Recreo Pharmaceuticals Llc behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
10.3 yr record
Peak capital year was 2017 with $3.0M across 1 filings.
Market position
ahead of 43% of Biotech / Pharma peers
Capital scale is ahead of 43% of Biotech / Pharma peers; modeled value is above 74% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2017: $3.0M across 1 filings.
  • Largest single filing was $3.0M on 2017-11-01.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotech / Pharma

Recreo Pharmaceuticals Llc is one of 227 Biotech / Pharma companies tracked from SUPERIOR. By capital raised it ranks mid-pack (ahead of 43% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
3
Investors (latest)
2013
Year incorporated
2017-11-01
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MPre-Seed · 2016-02-26 Raised $250K (real) Modeled valuation $13M (est)$250K$13MPre-Seed2016Seed · 2017-11-01 Raised $3.0M (real) Modeled valuation $123M (est)$3.0M$123MSeed2017+$3.0MCumulative $3.2M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$250K · 2016
Seed$3.0M · 2017

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$123.4M
Base estimate est.
$2.2M
Conservative case
$968.5M
Upside case
$15.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the biotech/pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $12.8M · 2016-02-262016Seed · modeled $123.4M · 2017-11-012017
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
33%
Survival probability
15% low · 51% high
1.71×/yr
Annual markup
2.24×/yr upside case
6.0 yr
Elapsed time used
8.7 yr actual, capped for stale marks
biotech/pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
20 mo
Avg between rounds
$1.9M/yr
Capital velocity
10.3 yr
On record since
2016
First round
2
Rounds on file
How it compares to the market

Benchmarked against 227 companies in Biotech / Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.6× of median
This company$3.2M
Sector median$5.6M
Latest round — vs other Seed rounds in sector (real $, this stage) 1.6× above median
This company$3.0M
Sector median$1.9M
Modeled value — vs sector median (estimate, all stages) 4.0× above median
This company$123.4M
Sector median$30.5M

Raised more than 43% of sector peers (real $). Modeled value above 74% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Vivacelle Bio, Inc. · Seed Raised $4.2M · modeled $119.5M (est)ClearLight Biotechnologies, LLC · Seed Raised $8.8M · modeled $113.9M (est)Base Pair Biotechnologies, Inc. · Seed Raised $1.9M · modeled $76.6M (est)Recreo Pharmaceuticals Llc (this company) Raised $3.2M · modeled $123.4M (est)Recreo Pharmaceuticals Llc
CompanyStageRaised · realValue · estvs peer med.
Recreo Pharmaceuticals Llc this companySeed$3.2M$123.4M1.06×
Vivacelle Bio, Inc.Seed$4.2M$119.5M1.02×
ClearLight Biotechnologies, LLCSeed$8.8M$113.9M0.98×
Base Pair Biotechnologies, Inc.Seed$1.9M$76.6M0.66×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$250K2016-02-26$1.4M$12.8M85%
Seed$3.0M2017-11-01$15.0M$123.4M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$250K2016-02-26
    • First recorded raise — entered as Pre-Seed.
    • 1 investor on this round.
  2. Seed$3.0M2017-11-01
    • Raised 20 mo later, in step with the ~15 mo sector norm.
    • Round 12.0× larger than the prior — scaling up.
    • 3 investors on this round.
Intelligence
2019 ~Q3
Modeled next raise · ~20mo cadence
$9.0M
Modeled next size est.range $5.9M$14.4M
12.0×
Last step-up
$1.9M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
QUING WU WEI2017-11
Tila Wei2016-02
Xiang Wang2016-02
Xiaochang Duan2016-02
Registry & provenance

Recreo Pharmaceuticals Llc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1668467
SEC CIK
2013
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Chirality Biosciences, Inc.Biotech / PharmaSeed$3.1M$7.4Msame sector · same stage
Cornovus Pharmaceuticals Inc.Biotech / PharmaSeed$3.1M$3.0Msame sector · same stage
Aruka Bio, Inc.Biotech / PharmaSeed$3.5M$19.0Msame sector · same stage
Klothea Bio, Inc.Biotech / PharmaSeed$2.9M$12.1Msame sector · same stage
Galatea Bio, Inc.Biotech / PharmaSeed$3.7M$16.2Msame sector · same stage
Yatiri Bio, Inc.Biotech / PharmaSeed$2.9M$18.1Msame sector · same stage
Teal Bio, Inc.Biotech / PharmaSeed$3.8M$1.5Msame sector · same stage
Catch Bio, Inc.Biotech / PharmaSeed$2.8M$1.5Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Abreos Biosciences, Inc.Biotech / PharmaSeries A$172.7M90%
Generex Biotechnology CorpPharmaceuticalsSeed$72.5M86%
Abrexa Pharmaceuticals, Inc.Biotech / PharmaSeries B$118.2M85%
Recida Therapeutics, Inc.BiotechnologySeries A$204.9M85%
Recode Therapeutics, Inc.BiotechnologySeries D+$215.4M84%
RecRe, Inc.OtherPre-Seed$1.5M83%
ReCor Medical, Inc.BiotechnologySeries B$873.2M82%
Rezo Therapeutics, Inc.BiotechnologySeries C$868.3M82%
Frequently asked
How much funding has Recreo Pharmaceuticals Llc raised?
Recreo Pharmaceuticals Llc has raised approximately $3.2M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Recreo Pharmaceuticals Llc's estimated valuation?
Provath's modeled valuation for Recreo Pharmaceuticals Llc is approximately $123.4M (modeled range $2.2M–$968.5M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Recreo Pharmaceuticals Llc at?
Recreo Pharmaceuticals Llc's latest modeled financing stage is Seed. Its most recent recorded round closed around Wed Nov 01.
What does Recreo Pharmaceuticals Llc do and where is it based?
Recreo Pharmaceuticals Llc operates in the Biotech / Pharma sector, based in SUPERIOR.
Explore related

See where Recreo Pharmaceuticals Llc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Recreo Pharmaceuticals Llc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.